Mortality among dialysis patients prescribed sevelamer hydrochloride and lanthanum carbonate compared with calcium-based phosphate binders: A retrospective cohort study using the Australian and New Zealand Dialysis and Transplant Database (ANZDATA).

All cause and cardiovascular mortality among Australian adult dialysis patients prescribed sevelamer hydrochloride and lanthanum carbonate compared with calcium-based phosphate binders.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ANZCTR

Registry ID

ACTRN12613000762752

Enrollment

15000

Registered

2013-07-09

Start date

2002-07-01

Completion date

2012-07-01

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The proposed study is a national, retrospective cohort study, which aims to determine if the introduction of non calcium-based phosphate binders sevelamer hydrochloride and lanthanum carbonate, since their PBS listing in 2007/2008, has been associated with a change in all-cause or cardiovascular disease mortality. We hypothesize that for patients on dialysis, most of whom require the use of phosphate binding medication, the progressive displacement of traditional calcium-based phosphate binders by the non calcium-based drugs sevelamer hydrochloride (Renagel) and lanthanum carbonate (Fosrenal) will have reduced cardiovascular and/or all-cause mortality after adjustment for covariates.

Interventions

This is a retrospective observational study to assess whether the introduction of non calcium based phosphate binders sevelamer hydrochloride (Renagel) and lanthanum carbonate (Fosrenal) over the past 6-7 years has influenced the mortality of patients on dialysis.

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Healthy volunteers

Inclusion criteria

Australian dialysis patients aged over 18 years of age and registered in ANZDATA registry will be included in the study.

Exclusion criteria

New Zealand patients and patients aged less than 18 years of age in ANZDATA registry will be excluded

Outcome results